EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Stock Analyst Ratings
TSX:EPRX • CA29842P1053
11.68 CAD
+0.5 (+4.47%)
Last: Feb 20, 2026, 07:00 PM
ChartMill assigns a Buy % Consensus number of 83% to EPRX.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 14.96. This target is 28.11% above the current price.
- EPRX.CA was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about EPRX.CA.
- In the previous month the buy percentage consensus was at a similar level.
- EPRX.CA was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-08 | Canaccord Capital | Downgrade | Buy |
| 2022-11-01 | Raymond James Capital | Upgrade | Outperform |
| 2022-06-09 | Raymond James Capital | Initiate | Outperform |
| 2022-04-21 | Canaccord Capital | Downgrade | Buy |
| 2022-04-01 | Raymond James Capital | Initiate | Outperform |
| 2021-11-12 | RaymondJamesFinancial | Downgrade | Outperform |
| 2021-08-18 | Canaccord Genuity | Downgrade | Buy |
| 2021-08-17 | Raymond James Financial | Initiate | Outperform |
EUPRAXIA PHARMACEUTICALS INC / EPRX.CA FAQ
Can you provide the average price target for EUPRAXIA PHARMACEUTICALS INC stock?
8 analysts have analysed EPRX.CA and the average price target is 14.96 CAD. This implies a price increase of 28.11% is expected in the next year compared to the current price of 11.68.
What is the consensus rating for EPRX stock?
The consensus rating for EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) stock?
The number of analysts covering EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) is 8.